Blindness Clinical Trial
Official title:
Do Blue-Blocking Lenses Block Colour From Our Lives? A Randomised Controlled Study Measuring Colour Vision Using the Gold Standard Colour Vision Test (an Anomaloscope)in Patients With Blue Light Filtering Intraocular Lenses (Tinted Yellow) and Comparing This With Patients Inserted With Clear, Non Blue Light Filtering Intraocular Lenses During Cataract Surgery
To measure colour vision in patients with a blue light filtering lens implant in one eye and non-tinted implant in the other eye (and compared this group with a control group with bilateral non-tinted implants) and to determine whether blue light filtering lenses limit colour vision
As we all age, the natural lens inside our eyes becomes denser, hazy and more yellow in
colour. In other words, cataracts develop. In order to enable clear vision again, cataract
surgery is performed. This involves removing the natural lens from the eye and replacing it
with a synthetic lens implant inside the eye. Cataract surgery with insertion of a lens
implant was first done in 1948 but didn't become routine until the early 1980s. Around this
time, awareness about the harmful effects of UV light were raised and by 1986, lens implants
routinely had a UV filter incorporated into them.1 As early as 1992, a study examining
patients who had had a high occupational exposure to blue and visible light, concluded that
there is a positive association between long term exposure to visible light and age related
wear and tear change at the back of the eye, termed age related macular degeneration (AMD).2
This theory was supported by several studies which have reported an increased rate of
progression of AMD in patients after cataract surgery with a clear lens implant (It is known
that clear lens implants transmit more blue light to the back of the eye compared with the
natural aging lens).3 Laboratory studies in 2000 showed that blue light causes damage to
aging retinal cells (the nerve cells at the back of the eye which are important in enabling
us to see), more so than green light or white light.4 Experimental studies with rats also
showed that exposure to blue light was 30 times more damaging to retinal cells compared with
yellow light.5 A further laboratory study in 2004 confirmed that by protecting aging retinal
cells with a blue light filtering lens, damage caused by blue light is prevented.6 Yellow
tinted, blue light filtering lens implants have been in production since 1991, first by Hoya
in Tokyo and now by Alcon as well. Alcon produce the Acrysof Natural lens implant which has
been designed to mimic the 53 year old natural lens and which received FDA and CE approval
in 2003. To date, over 2 million of these lenses have been implanted in patients world
wide.7 Although these lens implants are sometimes used in patients having cataract surgery
in the UK, this is not yet routine. One of the concerns about them is whether or not they
limit colour vision in any way. There have been some studies examining this and so far, none
of them have found a statistically significant difference in the colour vision between
patients with non-tinted lens implants and blue-filtering lens implants.8,9,10 However, none
of the studies thus far, have employed colour vision testing with an anomaloscope (which is
considered to be the gold standard colour vision test).11 In addition, none of them have
taken into account the level of capsular opacification (the capsule is a cling film bag-like
structure that supports the lens implant inside the eye and can over a period of time,
become thickened and hazy following cataract surgery) and the level of macular pigment
(yellow pigment which we have on the centre part of the back of our eyes which is thought to
contribute towards filtering blue light) in patients' eyes.
Age related macular degeneration is already the commonest cause of blindness in the UK. It
is a growing problem, particularly with our aging population and increasing levels of
ambient light which we are exposed to in our daily lives. Although the evidence is strongly
in favour of filtering blue light and the need for protective measures against AMD are
pressing, we need to be satisfied that there are no adverse effects of blocking blue from
our lives.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT02393118 -
A Study to Evaluate the BrainPort Vision Device in Individuals Blinded by Traumatic Injury
|
N/A | |
Terminated |
NCT00262509 -
Emergency Egress and Information System for Persons With Vision Loss
|
N/A | |
Terminated |
NCT00691444 -
Blind Child Melatonin Treatment Study
|
N/A | |
Recruiting |
NCT06237829 -
Testing Tactile Aids With Blind Subjects
|
N/A | |
Completed |
NCT00829036 -
Wayfinding Information Access System for People With Vision Loss
|
N/A | |
Completed |
NCT01488786 -
A Study to Evaluate the BrainPort® Vision Device in Subjects Who Are Blind
|
N/A | |
Completed |
NCT02643238 -
Continued Study of Artificial Vision: Evaluation of the BrainPort® System and Investigation of Visual Ambulation
|
N/A | |
Recruiting |
NCT06451172 -
Novel Antisense Oligonucleotide Eye Drops for Treating Antibiotic-Resistant Bacterial Keratitis
|
Early Phase 1 | |
Recruiting |
NCT04725760 -
Evaluation of the Efficacy of the BrainPort Vision Pro on the Performance of Daily Activities in the Profoundly Blind French Population
|
N/A | |
Recruiting |
NCT02983370 -
Development of a Cortical Visual Neuroprosthesis for the Blind
|
N/A | |
Not yet recruiting |
NCT06070467 -
Holistic Mixed Approaches to Capture the Real Life of Children With Rare Eye Diseases
|
||
Completed |
NCT01109576 -
Workshops for Veterans With Vision and Hearing Loss
|
Phase 0 | |
Completed |
NCT00920231 -
Computer Vision System for the Blind Veteran
|
Phase 1 | |
Terminated |
NCT00795236 -
Melatonin Studies of Totally Blind Children
|
N/A | |
Terminated |
NCT00634972 -
Efficient Study of ACULAR in Inhibiting Proliferative Retinopathy in Prematurity
|
Phase 4 | |
Enrolling by invitation |
NCT06364605 -
MySpace: the Role of Vision in Representing Space
|
N/A | |
Terminated |
NCT03913130 -
Extension Study to Study PQ-110-001 (NCT03140969)
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT05806684 -
Hyperbilirubinemia and Retinopathy of Prematurity in Preterm Infants: a Retrospective Study.
|
||
Completed |
NCT03753893 -
Ocular Manifestations in Rheumatic Diseases
|
||
Recruiting |
NCT04855045 -
An Open-label, Dose Escalation and Double-masked, Randomized, Controlled Trial Evaluating Safety and Tolerability of Sepofarsen in Children (<8 Years of Age) With LCA10 Caused by Mutations in the CEP290 Gene.
|
Phase 2/Phase 3 |